Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Treatment in Type 1 Diabetes in a Tertiary Care Center in Saudi Arabia.

Fallatah, Walla; Brema, Imad; Alobedallah, Ahmed; Alkhathami, Reem; Zaheer, Shawana; AlMalki, Eyad; Almehthel, Mohammed; Alzahrani, Saad; AlMalki, Mussa H

Fallatah, Walla; Brema, Imad; Alobedallah, Ahmed; Alkhathami, Reem; Zaheer, Shawana; AlMalki, Eyad; Almehthel, Mohammed; Alzahrani, Saad; AlMalki, Mussa H.

Afiliación

Fallatah W; Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Brema I; Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Alobedallah A; King Fahad Medical City, College of Medicine, King Saud Bin Abdul Aziz University for Health Science, Riyadh, Saudi Arabia.
Alkhathami R; Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Zaheer S; Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.
AlMalki E; Colleague of medicine, Shaqra University, Shaqra, Saudi Arabia.
Almehthel M; Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Alzahrani S; Division of Endocrinology, University of British Columbia.
AlMalki MH; Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.

Avicenna J Med ; 12(1): 10-15, 2022 Jan.

Article en En | MEDLINE | ID: mdl-35586391

Palabras clave

diabetic ketoacidosis; glycemic control; sodium-glucose co-transporter 2 inhibitors; type 1 diabetes mellitus; weight gain

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Avicenna J Med Año: 2022 Tipo del documento: Article País de afiliación: Arabia Saudita

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google